An assessment of therapeutic regimens in the treatment of acute exacerbations in chronic obstructive pulmonary disease and asthma

American Journal of Managed Care

Volumn 10, Issue SUPPL. 5, 2004, Pages

  Skrepnek, Grant H ^a,b   Skrepnek, Stan V ^c  

^a Dept of Pharmaceutical Sciences ^*  (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c East Texas Physicians Alliance LLP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; AMINOPHYLLINE; ANTIBIOTIC AGENT; BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BITOLTEROL; BRONCHODILATING AGENT; BUDESONIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; EXPECTORANT AGENT; FLUNISOLIDE; FLUTICASONE; FORMOTEROL; GLUCOCORTICOID; IPRATROPIUM BROMIDE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LEVALBUTEROL; MAGNESIUM SULFATE; METHYLPREDNISOLONE; METHYLXANTHINE; MUCOLYTIC AGENT; PIRBUTEROL; PREDNISOLONE; PREDNISONE; SALBUTAMOL; SALMETEROL; TERBUTALINE; TIOTROPIUM BROMIDE; TRIAMCINOLONE; UNINDEXED DRUG;

AIRWAY OBSTRUCTION; ASTHMA; BRONCHOSPASM; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; INFLAMMATION; META ANALYSIS; MORBIDITY; MORTALITY; OXYGEN THERAPY; POSITIVE END EXPIRATORY PRESSURE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TOXICITY;

ACUTE DISEASE; ASTHMA; HUMANS; PRACTICE GUIDELINES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 3242774749     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (148)

1. Skrepnek GH, Skrepnek SV. Epidemiology, clinical and economic burden, and natural history of chronic obstructive pulmonary disease and asthma. Am J Manag Care. 2004;10:S129-S138.
2. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, Updated 2003. National Heart, Lung, and Blood Institute, World Health Organization; 2003.
3. Snow V, Lascher S, Mottur-Pilson C. Evidence base for management of acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 2001; 134:595-599.
4. National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program (NAEPP). Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. National Institutes of Health Publication 97-4051. Bethesda, Md: US Department of Health and Human Services; 1997.
5. National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program (NAEPP). Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma. National Institutes of Health Publication 03-5074. Bethesda, Md: US Department of Health and Human Services; 2003.
6. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention, Updated 2003. National Institutes of Health Publication 02-3659. Bethesda, Md: US Department of Health and Human Services; 2002.
7. Guidelines on the management of asthma. Statement by the British Thoracic Society, the British Paediatric Association, the Research Unit of the Royal College of Physicians of London, the King's Fund Centre, the National Asthma Campaign, the Royal College of General Practitioners, the General Practitioners in Asthma Group, the British Association of Accident and Emergency Medicine, and the British Paediatric Respirator Group. Thorax. 1993;48:S1-S24.
8. British Thoracic Society, National Asthma Campaign, Research Unit of the Royal College of Physicians of London, King's Fund Centre. Guidelines on the management of asthma in adults II-acute severe asthma. Thorax. 1990;301:767-800.
9. National Heart, Lung, and Blood Institute. International consensus report on the diagnosis and management of asthma. Clin Ex Allergy. 1992;22(suppl):1s-72s.
10. MacNee W, Calverley PMA. Management of COPD. Thorax. 2003;58:261-265.
11. Blanchard AR. Treatment of acute exacerbations of COPD. Clin Cornerstone. 2003;5:28-36.
12. MacNee W. Acute exacerbations of COPD. Swiss Med Wkly. 2003;133:247-257.
13. Sciurba FC. Medical management of chronic obstructive pulmonary disease. Chest Surg Clin N Am. 2003;13:615-629.
14. Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J. 1995;8:1398-1420.
15. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1995;152 (suppl):77s-121s.
16. Sachs FL. Chronic bronchitis. Clin Chest Med. 1981;2:79-89.
17. Celli BR. Current thoughts regarding treatment of chronic obstructive pulmonary disease. Med Clin North Am. 1996;80:589-609.
18. Roy SR, Milgrom H. Managing outpatient asthma exacerbations. Curr Allergy Asthma Rep. 2003;3:179-189.
19. FitzGerald JM, Grunfeld A. Status asthmaticus. In: Lichenstein LM, Fauci, eds. Current Therapy in Allergy, Immunology, and Rheumatology. 5th ed. St Louis, Mo: Mosby; 1996.
20. Papiris S, Kotanidou A, Malagari K, Roussos C. Clinical review: severe asthma. Crit Care. 2002;6:30-44.
21. Volovitz B, Nussinovitch M. Management of children with severe asthma exacerbation in the emergency department. Paediatr Drugs. 2002;4:141-148.
22. McFadden ER, Elsanadi N, Dixon L, et al. Protocol therapy for acute asthma: therapeutic benefits and cost savings. Am J Med. 1995;99:651-661.
23. FitzGerald JM, Macklern P. Fatal asthma. Annu Rev Med. 1996;47:161-168.
24. Joseph KS, Blais L, Ernst P, et al. Increased morbidity and mortality related to asthma among asthmatic patients who use major tranquilizers. BMJ. 1996;312:79-82.
25. Rodrigo GJ, Rodrigo C, Hall JB. Acute asthma in adults: a review. Chest. 2004;125:1081-1102.
26. McCrory D, Brown C, Gelfand S, et al. Management of acute exacerbations of COPD: a summary and appraisal of published evidence. Chest. 2001;119:1190-1209.
27. 2-agonists versus ipratropium for acute exacerbations of COPD. Cochrane Database Syst Rev. 2003.
28. Turner MO, Patel A, Ginsberg S, et al. Bronchodilator delivery in acute airflow obstruction. A meta-analysis. Arch Intern Med. 1997;157:1736-1744.
29. Cates CJ, Rowe BH, Bara A. Holding chambers versus nebulizers for β-agonist treatment of acute asthma. Cochrane Database Syst Rev. 2002.
30. Newman KB, Milne S, Hamilton C, et al. A comparison of albuterol administered by metered dose inhaler and spacer with albuterol by nebulizer in adult patients presenting to an urban emergency department with acute asthma. Chest. 2002;121:1036-1041.
31. 2-agonists on clinical outcomes in chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2001;110(suppl):298S-303S.
32. 2-agonists as a potential option in the treatment of acute exacerbations of COPD. Pulm Pharmacol Ther. 2003;16:197-201.
33. Bach PB, Brown C, Gelfand SE, McCrory DC. Management of acute exacerbations of chronic obstructive pulmonary disease: a summary and appraisal of published evidence. Ann Intern Med. 2001;134:600-620.
34. Littner MR, Ilowite JS, Tashkin DP, et al. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive disease. Am J Respir Crit Care Med. 2000;161:1136-1142.
35. van Noord JA, Bantje T, Eland M, et al. A randomized controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. Thorax. 2000;55:289-294.
36. Maesen F, Smeets J, Sledsens F, et al. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Eur J Respir Dis. 1995;8:1506-1513.
37. Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax. 2003;58:399-404.
38. Vincken W, Can Noord JA, Greefhorst AP, et al. Improved health outcomes in patients with COPD during 1 year's treatment with tiotropium. Eur Respir J. 2002;19:209-216.
39. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002;19:217-224.
40. Barnes PJ. New treatments for COPD. Nat Rev Drug Discovery. 2002;1:437-446.
41. Kelly HW, Murphy S. β-adrenergic agonists for acute, severe asthma. Ann Pharmacother. 1992;26:81-91.
42. 2-agonists for acute asthma in the emergency department. Cochrane Database Syst Rev. 2001.
43. Rodrigo GJ, Rodrigo C. Continuous versus intermittent β-agonists in the treatment of acute adult asthma: a systematic review with meta-analysis. Chest. 2002;122: 160-165.
44. Kercsmar CM. Current trends in management of pediatric asthma. Respir Care. 2003;48:194-205.
45. Rodrigo G, Rodrigo C, Burschtin O. Ipratropium bromide in adults with acute asthma: a meta-analysis of randomized controlled trials. Am J Med. 1999;107:363-370.
46. Karpel JP, Schacter EN, Fanta C, et al. A comparison of ipratropium and albuterol versus albuterol alone for the treatment of acute asthma. Chest. 1996;10:611-616.
47. Lanes SF, Garrett JE, Wentworth CE III, FitzGerald JM, Karpel JP. Effect of adding ipratropium bromide to salbutamol in the treatment of acute asthma: a pooled analysis of three trials. Chest. 1998;114:65-72.
48. 2 agonists for treating acute childhood and adolescent asthma? A systematic review. BMJ. 1998;317:971-977.
49. Rodrigo GJ, Rodrigo C. First-line therapy for adult patients with acute asthma receiving multiple-dose protocol of ipratropium bromide plus albuterol in the emergency department. Am J Respir Crit Care Med. 2000;161: 1862-1868.
50. Rodrigo GJ, Rodrigo C. The role of anticholinergics in acute asthma treatment: an evidence-based evaluation. Chest. 2002;121:1977-1987.
51. Kelly HW, Sorkness CA. Asthma. In: DiPiro JT, Talbert RL, Yee GC, et al, eds. Pharmacotherapy: A Pathophysiologic Approach. New York, NY: McGraw-Hill; 2002.
52. 2-agonists for initial treatment of acute asthma in children. Cochrane Database Syst Rev. 2000.
53. Schuh S, Johnson DW, Callaha S, Canny G, Levison H. Efficacy of frequent nebulized ipratropium added to high dose albuterol therapy in severe childhood asthma. J Pediatr. 1995;126:639-645.
54. Qureshi F, Pestian J, Davis P, Zaritsky A. Effect of nebulized ipratropium on the hospitalization rates of children with asthma. N Engl J Med. 1998;339:1030-1035.
55. Goggin N, Macarthur C, Parkin PC. Randomized trial of the addition of ipratropium bromide to albuterol and corticosteroid therapy in children hospitalized because of an acute asthma exacerbation. Arch Pediatr Adolesc Med. 2001;155:1329-1334.
56. Craven D, Kercsmar CM, Myers RT, et al. Ipratropium bromide plus nebulized albuterol for the treatment of hospitalized children with acute asthma. J Pediatr. 2001;138:51-58.
57. Streetman DD, Bhatt-Mehta V, Johnson CE. Management of acute, severe asthma in children. Ann Pharmacother. 2002;36:1249-1260.
58. Rebuck A, Chapman K, Abboud R, et al. Nebulized anticholinergic and sympathomimetic treatment of asthma and chronic obstructive airways disease in the emergency room. Am J Med. 1987;82:59-64.
59. Handley DA, Tinkelman D, Noonan M, et al. Dose-response evaluation of levalbuterol versus racemic albuterol in patients with asthma. J Asthma. 2000;37: 319-327.
60. Milgrom H, Skoner DP, Bensch G, et al. Low-dose levalbuterol in children with asthma: safety and efficacy in comparison with placebo and racemic albuterol. J Allergy Clin Immunol. 2001;108:938-945.
61. Handley DA. Single-isomer beta-agonists. Pharmacotherapy. 2001;21(suppl):21S-27S.
62. Carl JC, Myers TR, Kirchner HL, Kercsmar CM. Comparison of racemic albuterol and levalbuterol for treatment of acute asthma. J Pediatr. 2003;143:731-736.
63. Truitt T, Witko T, Halpern M. Levalbuterol compared to racemic albuterol: efficacy and outcomes in patients hospitalized with COPD or asthma. Chest. 2003;123:128-135.
64. Nowak RM, Emerman CL, Schaefer K, et al. Leval-buterol compared with racemic albuterol in the treatment of acute asthma: results of a pilot study. Am J Emerg Med. 2004;22:29-36.
65. 2-agonists: efficacy, safety, and patient preference. Pharmacotherapy. 2004; 24(suppl):S44-S54.
66. Page CP, Morley J. Contrasting properties of albuterol stereoisomers. J Allergy Clin Immunol. 1999:104(suppl): S31-S41.
67. Templeton A, Chapman l, Chilvers E, et al. Effects of S-salbutamol on isolated human bronchus. Pulm Pharmacol Ther. 1998;11:1-6.
68. Lotvall J, Palmqvist M, Arvidsson P, et al. The therapeutic ratio of R-albuterol is comparable with that of RS-albuterol in asthmatic patients. J Allergy Clin Immunol. 2001;108:726-731.
69. Nelson H, Bensch G, Pleskow WW, et al. Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma. J Allergy Clin Immunol. 1998;102:943-952.
70. Barr RG, Rowe BH, Camargo CA Jr. Methylxanthines for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2001.
71. 2-agonists in adults with acute asthma. Cochrane Database Syst Rev. 2000.
72. Kelly HW, Murphy SJ. The management of acute severe asthma in children. In: Busse WW, Holgate ST, eds. Asthma and Rhinitis. Boston, Mass: Blackwell Science; 2001.
73. Thompson WH, Nielson CP, Carvalho P, Charan NB, Crowley JJ. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med. 1996;154:407-412.
74. Davies L, Angus RM, Calverly PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomized controlled trial. Lancet. 1999;354:456-460.
75. Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations in chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med. 1996;154:407-412.
76. Wood-Baker R, Walters EH, Gibson P. Oral corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2003.
77. Singh JM, Palda VA, Stanbrook MB, Chapman KR. Corticosteroid therapy for patients with acute exacerbations of chronic obstructive pulmonary disease: a systematic review. Arch Intern Med. 2002;162:2527-2536.
78. Maltais F, Ostinelli Bourbeau J, et al. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med. 2002;165: 698-703.
79. Sutherland ER, Allmers H, Ayas NT, Venn AI, Martin RJ. Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis. Thorax. 2003;58: 937-941.
80. Adcock IM, Chung KF. Why are corticosteroids ineffective in COPD? Curr Opin Investig Drugs. 2002;3:58-60.
81. Rodrigo G, Rodrigo C. Inhaled flunisolide for acute severe asthma. Am J Respir Crit Care Med. 1998;157: 2201-2203.
82. FitzGerald JM, Shragge D, Haddon J, et al. A randomized controlled trial of high dose, inhaled budesonide versus oral prednisone in patients discharged from the emergency department following an acute asthma exacerbation. Can Respir J. 2000;7:61-67.
83. Chipps BE, Chipps DR. A review of the role of inhaled corticosteroids in the treatment of acute asthma. Clin Pediatr. 2001;40:185-189.
84. Edmonds ML, Camargo CA Jr, Pollack CV Jr, Rowe BH. Early use of inhaled corticosteroids in the emergency department treatment of acute asthma. Cochrane Database Syst Rev. 2003.
85. Schuh S, Reisman J, Alshehri M, et al. A comparison of inhaled fluticasone and oral prednisone for children with severe acute asthma. N Engl J Med. 2000;343:689-694.
86. Hendeles L, Sherman J. Are inhaled corticosteroids effective for acute exacerbations of asthma in children? J Pediatr. 2003;142(suppl):26S-33S.
87. Rachelefsky G. Treating exacerbations of asthma in children: the role of systemic corticosteroids. Pediatrics. 2003;112:382-397.
88. Rowe BH, Spooner C, Ducharme FM, Bretzlaff JA, Bota GW. Early emergency department treatment of acute asthma with systemic corticosteroids. Cochrane Database Syst Rev. 2001.
89. Kelly HW, Murphy S. Corticosteroids for acute severe asthma. DICP. 1991;25:72-79.
90. Hendeles L. Selecting a systemic corticosteroid for acute asthma in young children. J Pediatr. 2003;142 (suppl):40S-44S.
91. Patel IS, Seemungal TA, Wilks M, et al. Relationship between bacterial colonization and the frequency, character, and severity of COPD exacerbations. Thorax. 2002;57:759-764.
92. Saint S, Bent S, Vittinghoff E, Grady G. Antibiotics in chronic obstructive pulmonary disease. A meta analysis. JAMA. 1995;273:957-960.
93. MacFarlane JT, Colville A, Guion A, MacFarlane RM, Rose DH. Prospective study of aetiology and outcome of adult lower respiratory tract infections in the community. Lancet. 1993;341:511-514.
94. Graham V, Lasserson T, Rowe BH. Antibiotics for acute asthma. Cochrane Database Syst Rev. 2001.
95. Freymuth F, Vabert A, Brouard J, et al. Detection of viral, Chlamydia pneumoniae and Mycoplasma pneumoniae infections in exacerbations of asthma in children. J Clin Virol. 1999;13:131-139.
96. Nicholson K, Kent J, Ireland D. Respiratory viruses and exacerbations of asthma in adults. BMJ. 1993;307: 982-986.
97. Johnston SL, Pattermore PK, Sanderson G, et al. Community study of the role of viral infections in exacerbations of asthma in 9-11 year old children. BMJ. 1995;310:1225-1229.
98. Weinberger M. Treatment strategies for viral respiratory infection-induced asthma. J Pediatr. 2003;142 (suppl):S34-S39.
99. Rowe BH, Bretzlaff JA, Bourdon C, et al. Intravenous magnesium sulfate treatment for acute asthma in the emergency department: a systematic review of the literature. Ann Emerg Med. 2000;36:181-190.
100. Rodrigo GJ, Rodrigo C, Burschtin O. Intravenous magnesium as an adjuvant in acute bronchospasm: a meta-analysis of randomized trials. Am J Emerg Med. 2000;18:216-221.
101. Silverman RA, Osborn H, Runge J, et al. IV magnesium sulfate in the treatment of acute severe asthma: a multicenter randomized controlled trial. Chest. 2002;122:489-497.
102. Brochard L. Noninvasive ventilation for acute respiratory failure. JAMA. 2002;288:932-935.
103. Lightowler JV, Wedzicha JA, Elliot MW, Ram FS. Non-invasive positive pressure ventilation to treat respiratory failure from exacerbations of chronic obstructive pulmonary disease: Cochrane systematic review and meta analysis. BMJ. 2003;326:185-189.
104. Plant PK, Owen JL, Elliot MW. Early use of noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multicentre randomized controlled trial. Lancet. 2000;355:1931-1935.
105. Fernandez MM, Villagral A, Blanchl L, et al. Noninvasive mechanical ventilation in status asthmaticus. Intensive Care Med. 2001;27:486-492.
106. Soroksky A, Stav D, Shpirer I. A pilot prospective, randomized, placebo-controlled trial of bilevel positive airway pressure in acute asthmatic attack. Chest. 2003;123:1018-1025.
107. British Thoracic Society Standards of Care Committee. Non-invasive ventilation in acute respiratory failure. Thorax. 2002;57:192-211.
108. Poole PJ, Black PN. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2003.
109. Tassaux D, Jolliet P, Roeseler J. Effects of helium-oxygen on intrinsic positive end-expiratory pressure in intubated and mechanically ventilated patients with severe chronic obstructive pulmonary disease. Crit Care Med. 2000;28:2721-2728.
110. Ho AMH, Lee A, Karmakar MK, et al. Heliox versus air-oxygen mixtures for the treatment of patients with acute asthma: a systematic review. Chest. 2003;123: 882-890.
111. Rodrigo GJ, Rodrigo C, Pollack CV, Rowe B. Use of helium-oxygen mixtures in the treatment of acute asthma: a systematic review. Chest. 2003;123:891-896.
112. Ducharme FM. Anti-leukotrienes as add-on therapy to inhaled glucocorticoids in patients with asthma: systematic review of current evidence. BMJ. 2002;324:1-7.
113. Foresi A, Paggiaro P. Inhaled corticosteroids and leukotriene modifiers in the acute treatment of asthma exacerbations. Curr Opin Pulm Med. 2003;9:52-56.
114. Camargo CA, Smithline MA, Malice MP, et al. A randomized controlled trial of intravenous montelukast in acute asthma. Am J Respir Crit Care Med. 2003; 166:528-533.
115. Dempsey OJ, Lipworth BJ. Intravenous montelukast in acute asthma: expensive aminophylline? Thorax. 2000;55:808-809.
116. Rowe BH, Edmonds ML, Spooner CH, Camargo CA. Evidence-based treatments for acute asthma. Respir Care. 2001;46:1380-1390.
117. 1. The Lung Health Study. JAMA. 1994;272:1497-1505.
118. Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med. 1994;331:778-784.
119. Ramsey SD. Suboptimal medical care in COPD: exploring the causes and consequences. Chest. 2000; 117(suppl):S33-S37.
120. Rowe BH, Bota GW, Fabris L, Therrien SA, Milner RA, Jacono J. Inhaled budesonide in addition to oral corticosteroids to prevent asthma relapse following discharge from the emergency department: a randomized controlled trial. JAMA. 1999;281:2119-2126.
121. Sin DD, Man SF. Low-dose inhaled corticosteroid therapy and risk of emergency department visits for asthma. Arch Intern Med. 2003;162:1591-1595.
122. Smith MJ, Rascati KL, McWilliams BC. Inhaled anti-inflammatory pharmacotherapy and subsequent hospitalizations and emergency department visits among patients with asthma in the Texas Medicaid program. Ann Allergy Asthma Immunol. 2004;92:40-46.
123. Freund DA, Stein J, Hurley R, Engel W, Woomert A, Lee B. Specialty differences in the treatment of asthma. J Allergy Clin Immunol. 1989;84:401-406.
124. Zeiger RS, Heller S, Mellon MH, Wald J, Falkoff R, Schatz M. Facilitated referral to asthma specialist reduces relapses in asthma emergency room visits. J Allergy Clin Immunol. 1991;87:1160-1168.
125. Mahr TA, Evans R 3rd. Allergist influence on asthma care. Ann Allergy. 1993;71:115-120.
126. Westley CR, Spiecher B, Starr L, et al. Cost effectiveness of an allergy consultation in the management of asthma. Allergy Asthma Proc. 1997;18:15-18.
127. Vollmer WM, O'Hollaren M, Ettinger KM, et al. Specialty differences in the management of asthma. A cross-sectional assessment of allergists' patients and generalists' patients in a large HMO. Arch Intern Med. 1997;157:1201-1208.
128. Kelly CS, Morrow AL, Shults J, Nakas N, Strope GL, Adelman RD. Outcomes evaluation of a comprehensive intervention program for asthmatic children enrolled in Medicaid. Pediatrics. 2000;105:1029-1035.
129. Schatz M, Cook EF, Nakahiro R, Petitti D. Inhaled corticosteroids and allergy specialty care reduce emergency hospital use for asthma. J Allergy Clin Immunol. 2003;111:503-508.
130. Ziedalski TM, Sankaranarayanan V, Chitkara RK. Advances in the management of chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2003; 4:1063-1082.
131. Barnes PJ. New treatments for COPD. Nat Rev Drug Discovery. 2002;1:437-446.
132. Di Maria G, Spicuzza L, Mazzarella G. Future treatment of chronic obstructive pulmonary disease. Monaldi Arch Chest Dis. 2002;57:200-205.
133. Friedman M. Future treatment strategies for COPD. Clin Cornerstone. 2003;5:45-51.
134. DeKorte CJ. Current and emerging therapies for the management of chronic inflammation in asthma. Am J Health-Syst Pharm. 2003;60:1949-1959.
135. Sullivan SD, Meltzer EO. Emerging therapeutic strategies for asthma management. J Manag Care Pharm. 2003;9(suppl):S14-S21.
136. Kips JC. Cytokines in asthma. Eur Respir J. 2001;18(suppl):S24-S33.
137. Kips JC, Tournoy KG, Pauwels RA. New anti-asthma therapies: suppression of the effect of interleukin (IL)-4 and IL-5. Eur Respir J. 2001;17:499-506.
138. Peccini F, Dottorini ML, Casucci G, et al. Ineffectiveness of a four-week treatment with the thromboxane synthetase inhibitor, imidazole salycilate, in reducing airway hyperresponsiveness to methacholine in asthmatics. Monaldi Arch Chest Dis. 1997;52:130-137.
139. Giembycz MA. Cilomilast. A second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease. Expert Opin Invest Drugs. 2001;10:1361-1379.
140. Jackson DY. Alpha 4 integrin antagonists. Curr Pharm Des. 2002;8:1229-1253.
141. Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH. Anti-IgE for chronic asthma. Cochrane Database Syst Rev. 2004.
142. Donahue JG, Weiss ST, Livingston JM, Goetsch MA, Greineder DK, Platt R. Inhaled steroids and the risk of hospitalization for asthma. JAMA. 1997;277:887-891.
143. Blais L, Ernst P, Boivin JF, Suissa S. Inhaled corticosteroids and the prevention of readmission to hospital for asthma. Am J Respir Crit Care Med. 1998;158:126-132.
144. Suissa S, Ernst P, Kezouh A. Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma. Thorax. 2002;57:880-884.
145. Lieu TA, Quesenberry CP Jr, Capra AM, Sorel ME, Martin KE, Mendoza GR. Outpatient management practices associated with reduced risk of pediatric asthma hospitalization and emergency department visits. Pediatrics. 1997;100(3 pt 1):334-341.
146. Cowie RL, Revitt SG, Underwood MF, Field SK. The effect of a peak flow-based action plan in the prevention of exacerbations of asthma. Chest. 1997;112: 1534-1538.
147. Adams RJ, Smith BJ, Ruffin RE. Factors associated with hospital admissions and repeat emergency department visits for adults with asthma. Thorax. 2000;55:566-573.
148. Abramson MJ, Bailey MJ, Couper FJ, et al. Are asthma medications and management related to deaths from asthma? Am J Respir Crit Care Med. 2001;163:12-18.